Clinical Pipeline


ADXS-cHER2 Clinical Program

ADXS-cHER2 is currently in pre-clinical development for the treatment of HER2 over-expressing human cancers, including breast cancer.

ADXS-cHER2 is an immunotherapy that targets HER2 over-expressing cancers. The antigen in ADXS-cHER2 is a combination antigen, combining two external and three internal binding epitopes of the HER-2 peptide into a truncated combination peptide fused to truncated LLO. By incorporating HER2 into the Advaxis live, attenuated vector, Advaxis intends to deliver the HER2 antigen fused to the powerful immunostimulant LLO, directly inside antigen presenting cells that are capable of driving a cellular immune response to HER2 over-expressing cells. The Advaxis approach is also designed to inhibit the Treg and MDSC cells specifically in the tumors that have been promoting immunologic tolerance of the cancer.